TBCRC 008: Early Change in (18)F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2–Negative Primary Operable Breast Cancer

Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neo-adjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Nucl Med
Autors principals: Connolly, Roisin M., Leal, Jeffrey P., Goetz, Matthew P., Zhang, Zhe, Zhou, Xian C., Jacobs, Lisa K., Mhlanga, Joyce, Joo, H O, Carpenter, John, Storniolo, Anna Maria, Watkins, Stanley, Fetting, John H., Miller, Robert S., Sideras, Kostandinos, Jeter, Stacie C., Walsh, Bridget, Powers, Penny, Zorzi, Jane, Boughey, Judy C., Davidson, Nancy E., Carey, Lisa A., Wolff, Antonio C., Khouri, Nagi, Gabrielson, Edward, Wahl, Richard L., Stearns, Vered
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4352313/
https://ncbi.nlm.nih.gov/pubmed/25476537
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.114.144741
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars